A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 29, Issue 5, 2002, Pages 373-377

  Antin, J H ^a   Lee, S J ^a   Neuberg, D ^a   Alyea, E ^a   Soiffer, R J ^a   Sonis, S ^a   Ferrara, J L M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Graft versus host disease; Interleukin 11; Stem cell transplantation

Indexed keywords

ACICLOVIR; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FUROSEMIDE; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 11; INTERLEUKIN 11; RECOMBINANT PROTEIN;

ACUTE DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIURESIS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EDEMA; FEMALE; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUICIDE; WEIGHT GAIN; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; BODY FLUID; DRUG COMBINATION; DRUG EFFECT; METHODOLOGY; MIDDLE AGED; MORTALITY; PILOT STUDY; STEM CELL TRANSPLANTATION; STOMATITIS; TREATMENT OUTCOME;

ADULT; BODY FLUIDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INTERLEUKIN-11; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PILOT PROJECTS; PLACEBOS; RECOMBINANT PROTEINS; STEM CELL TRANSPLANTATION; STOMATITIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 85047683496     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703394     Document Type: Article

References (32)

1. In vivo and in vitro production of IFN-beta and IFN-gamma during graft vs host disease
2. Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro skin explant model
3. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNFα) release in the prophylactic application of a monoclonal antibody neutralizing TNFα (MAK 195F)
4. The role of keratinocyte cytokines in inflammation and immunity
5. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease
6. TNFα levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD
7. A study of cytokine production in acute graft-vs-host disease
8. Interleukin-12 inhibits murine graft-versus-host disease
9. Interleukin-12 prevents severe acute gradt-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mismatched murine bone marrow transplantation model
10. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice
11. Recombinant interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease
12. A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease
13. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T-lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-verus-host disease
14. Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters
15. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation
16. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation
17. IL-11 reduces the severity of graft-versus-host disease following allogeneic BMT
18. IBMTR severity index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade
19. 1994 Consensus Conference on Acute GVHD Grading
20. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation
21. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients
22. Interleukin-11 induces intestinal epithelial cell grwoth arrest though effects on retinoblastoma protein phophorylation
23. A bone marrow stroma-derive growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy
24. Interleukin-11 protects the clonogenic stem cells in murine small-intestinal crypts from impairment of their reproductive capacity by radiation
25. Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation
26. Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis
27. Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time
28. Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11
29. Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters
30. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic marrow transplants
31. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer
32. Mechanism and amelioration of recombinant human interleukin-11 (rhIL-11)-induced anemia in healthy subjects